![【重磅录像】颜宁:“AI在结构生物学中的未达之地”](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![口服JAK抑制剂2期结果顶线,有望挑战十届药王修美乐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![口服JAK抑制剂2期结果顶线,有望挑战十届药王修美乐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![口服JAK抑制剂2期结果顶线,有望挑战十届药王修美乐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
参考资料:
-
Incyte官网
-
Incyte says under-the-radar JAK inhibitor clears a high bar for skin disorder
-
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa -
其他公开资料
![口服JAK抑制剂2期结果顶线,有望挑战十届药王修美乐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![口服JAK抑制剂2期结果顶线,有望挑战十届药王修美乐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![口服JAK抑制剂2期结果顶线,有望挑战十届药王修美乐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
阿尔茨海默病、癌症……看「新型自噬降解剂」的研究进展,这是继PROTAC之后又一新起之秀
![口服JAK抑制剂2期结果顶线,有望挑战十届药王修美乐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
新冠疫情还会再来?到那时又该吃什么药?
![口服JAK抑制剂2期结果顶线,有望挑战十届药王修美乐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
罗氏制药部门负责人出任拜耳CEO,两家企业未来走向何方?
![口服JAK抑制剂2期结果顶线,有望挑战十届药王修美乐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
彭博社流出「小道消息」,惊天收购案浮现
![口服JAK抑制剂2期结果顶线,有望挑战十届药王修美乐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
专栏 | 柳达:40 年辉煌史,生物药的开发有无范式?
点击这里,报名创新药BD高阶研讨会【上海站】!
本篇文章来源于微信公众号:药时代
发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权